Aarhus University Seal / Aarhus Universitets segl

Organisational barriers to thrombolysis treatment of acute ischaemic stroke

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

DOI

BACKGROUND: Intravenous thrombolysis with fibrinolytic drugs such as alteplase is not implemented widely in any country although the treatment is both effective and cost-effective in selected patients within a 3-h window after acute ischaemic stroke. The purpose of the present study was to describe the organisational barriers to delivery of thrombolysis for acute ischaemic stroke with special regard to the Danish healthcare system.

METHOD: Systematic and unsystematic searches of medical, economic and grey literature on organisational barriers to thrombolysis treatment were performed in Cochrane, PubMed, EMBASE, Cinahl, Econlit, NHS EED, SvedMed+ and the Health Technology Assessment (HTA) database. The search periods were 1996-2006.

FINDINGS: Three main types of literature on organisational barriers were found: medical literature including HTA reports on barriers related to the 3-h window, economic literature on barriers related to the lack of capacity to provide the treatment on a 24-h basis, and grey literature/policy papers on standards and demands to the hospitals and healthcare systems who implements the treatment.

CONCLUSION: Information on organisational barriers can be extracted from different types of literature (medical, economic and grey literature/policy papers), but organisational barriers are most often not the primary study objective in the relevant literature. This review showed a broad spectrum of possible organisational barriers to the delivery of thrombolysis treatment of acute ischaemic stroke.

Original languageEnglish
JournalCurrent Medical Research and Opinion
Volume23
Issue11
Pages (from-to)2833-9
Number of pages7
ISSN0300-7995
DOIs
Publication statusPublished - Nov 2007

    Research areas

  • Brain Ischemia, Denmark, Fibrinolytic Agents, Humans, Stroke

See relations at Aarhus University Citationformats

ID: 102080380